Ishan Health Biotec Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.92 M
- Revenue Growth 16.51%
- Profit Growth 37.03%
- Ebitda -529.75%
- Net Worth 73.04%
- Total Assets 32.12%
About Ishan Health Biotec
Ishan Health Biotec Private Limited (IHBPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 December 2008 and has a history of 16 years and two months. Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.92 M.
Swapna More, Narendra More, and Supriya Chandratre serve as directors at the Company.
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85100MH2008PTC188976
- Company No.
188976
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ishan Health Biotec?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swapna More  | Director | 23-Feb-2017 | Current |
| Narendra More | Director | 17-Dec-2008 | Current |
| Supriya Chandratre | Director | 17-Dec-2008 | Current |
Financial Performance of Ishan Health Biotec.
Ishan Health Biotec Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 16.51% increase. The company also saw a substantial improvement in profitability, with a 37.03% increase in profit. The company's net worth Soared by an impressive increase of 73.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ishan Health Biotec?
In 2017, Ishan Health Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.92 M
₹0
Charges Breakdown by Lending Institutions
- Uco Bank : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2017 | Uco Bank | ₹0.92 M | Open |
How Many Employees Work at Ishan Health Biotec?
Unlock and access historical data on people associated with Ishan Health Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ishan Health Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ishan Health Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
